LPCN Latest Press Releases

-- April 6, 2026 --

Lipocine Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses Globe Newswire 7:56 AM

-- April 2, 2026 --

Lipocine Reports Topline Safety and Efficacy Results for LPCN 1154 in Patients with Postpartum Depression PRNewswire 8:00 AM

-- March 10, 2026 --

Lipocine Announces Financial Results for the Full Year Ended December 31, 2025 PRNewswire 8:00 AM

-- February 18, 2026 --

Lipocine Announces Last Patient Last Visit in Pivotal Phase 3 Trial of LPCN 1154 for Postpartum Depression (PPD) PRNewswire 8:00 AM

-- January 20, 2026 --

Lipocine Announces Completion of Enrollment and Dosing in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD) PRNewswire 8:00 AM

-- January 19, 2026 --

2026 Asset Growth: Why Federal Compliance Is the New Metric Globe Newswire 12:20 PM

-- January 12, 2026 --

Lipocine Reports Encouraging Progress Post Second Interim Safety Review in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD) PRNewswire 8:00 AM

-- December 16, 2025 --

Lipocine's PPD Phase 3 Study (LPCN 1154) Hits 80% Enrollment Milestone PRNewswire 8:00 AM

-- November 18, 2025 --

Lipocine Highlights Promising Interim Safety Profile in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD) PRNewswire 8:00 AM

Market Data Delayed 15 Minutes

Questions? Feedback?Olark live chat software